The first batch of drug 2-deoxy-D-glucose drug to treat Covid-19 patients will be launched today. The drug has been developed by the Defence Research and Development Organisation (DRDO) in collaboration with Dr Reddy's Laboratories (DRL).
The 2-DG (2-deoxy-D-glucose) is an anti-COVID-19 therapeutic application of the drug. It has been developed by DRDO and Dr Reddy's Laboratories.
"The two aircraft carrying zeolite from Rome arrived as the first consignment of the key component," a DRDO official told IANS.
The first batch of anti-COVID drug 2-DG, developed by the DRDO, will be released on Monday (May 17) by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan, officials said.
At a time when country battles with the second wave of coronavirus, the first batch of 10,000 doses of 2DG medicine for curing COVID-19 patients would be launched early next week and will be given to patients, DRDO officials informed on Friday.
The 2-DG drug developed by the Defence Research and Development Organisation (DRDO) could be a game-changer in the fight against COVID, Karnataka Health Minister Dr K Sudhakar said on Friday.
The recruitment drive is being conducted for 79 vacancies. The candidates can apply through the website- drdo.gov.in
The government on Wednesday approved the procurement of 1,50,000 units of 'Oxycare' system developed by the Defence Research and Development Organisation (DRDO) to help in the treatment of COVID-19 patients.
In view of the increasing requirements of facilities for critical COVID-19 patients, the Defence Research and Development Organisation's makeshift COVID hospital with 250 ICU beds is operational from May 10.
DRDO has developed an Artificial Intelligence algorithm that can detect the presence of COVID-19 disease in Chest X-rays. Named ATMAN AI, the tool was developed by DRDO's Centre for Artificial Intelligence and Robotics (CAIR), with the support of 5C Network & HCG Academics.
Based on these results, the DCGI's Central Drugs Standard Control Organisation (CDSCO) permitted Phase-II clinical trial of 2-DG in COVID-19 patients in May 2020. The ministry said the DRDO, along with DRL started the clinical trials to test the safety and efficacy of the drug in COVID-19 patients.
The Drugs Controller General of India has approved an anti-COVID oral drug, developed by DRDO, for emergency use as adjunct therapy in moderate to severe coronavirus patients, the defence ministry said on Saturday. It said clinical trials of the drug 2-deoxy-D-glucose (2-DG) showed that it helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
Drugs Controller General of India (DCGI) on May 08 approved emergency use DRDO's anti-COVID drug which the agency said will be helpful in faster recovery of hospitalised patients. While speaking to ANI, Institute of Nuclear Medicine and Allied Sciences (INMAS-DRDO) scientists spoken about drug 2-deoxy-D-glucose (2-DG). The drug will be of immense benefit to the people suffering from COVID-19.
The drug has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's Laboratories in Hyderabad.
The Drugs Controller General of India has approved an anti-COVID oral drug, developed by DRDO, for emergency use as adjunct therapy in moderate to severe coronavirus patients, the defence ministry said on Saturday. It said clinical trials of the drug 2-deoxy-D-glucose (2-DG) showed that it helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
The drug has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's Laboratories in Hyderabad.
DRDO has developed an Artificial Intelligence algorithm that can detect the presence of COVID-19 disease in Chest X-rays.
Union Health Minister Harsh Vardhan inspects the high-flow medical oxygen plant that has been set up DRDO at RML Hospital.
DRDO director Narendra Kumar Arya said, "The makeshift hospital at Awadh Shilpgram in Lucknow will be operational from Wednesday noon. The hospital has the capacity of 500 beds, including 150 ICU and 350 general beds which are also equipped with oxygen."
India is struggling with the second wave of the coronavirus infection as hospitals in several states are reeling under a severe shortage of oxygen, drugs, equipment and beds.
Top News
Latest News
